Lobe Sciences Shareholders Approve Key Initiatives at Annual Meeting

Vancouver-based Lobe Sciences Ltd. announced the outcomes of its Annual General and Special Meeting held on July 30, 2026. During the meeting, attended by holders of 152,807,032 common shares, several resolutions were passed. These included the re-election of directors and the re-appointment of auditors.

Key decisions encompassed approval of a new Long-Term Incentive Plan, reducing share-based compensation from 40% to 20%, designed to better align with shareholder interests. Additionally, amendments to the Company's constating documents received strong support, including eliminating preferred shares to simplify the capital structure.

Management also provided updates on strategic initiatives, including preclinical and regulatory efforts for programs under subsidiaries Cynaptec Pharmaceuticals and Applied Lipid Therapeutics. The Company reiterated its focus on pharmaceutical asset development to enhance shareholder value and discussed potential senior exchange listing plans.